The Struggle for Transparency in Drug Regulation

This chapter explores the conflict between the Cochrane collaboration and the European Medicines Agency over access to clinical data on weight loss drugs. It highlights the European Ombudsman's ruling against the EMA for maladministration and the implications for patient safety and regulatory transparency.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app